Table 2.
Baseline clinical characteristics of patients after PSM.
| Characteristic* | Therapy | P-value | |
|---|---|---|---|
| Resection-based (n = 72) | Sorafenib-based (n = 72) | ||
| Age (y) | 0.238 | ||
| ≤50 | 27 (37.5) | 34 (47.2) | |
| >50 | 45 (62.5) | 38 (52.8) | |
| Gender | 1.000 | ||
| Female | 5 (6.9) | 5 (6.9) | |
| Male | 67 (93.1) | 67 (93.1) | |
| HBsAg | 0.061 | ||
| Negative | 19 (26.4) | 10 (13.9) | |
| Positive | 53 (73.6) | 62 (86.1) | |
| HBVDNA | 0.133 | ||
| ≤103 | 33 (45.8) | 42 (58.3) | |
| >103 | 39 (54.2) | 30 (41.7) | |
| Cirrhosis | 0.218 | ||
| None or mild | 28 (38.9) | 21 (29.2) | |
| Moderate or severe | 44 (61.1) | 51 (70.8) | |
| Ascites | 0.275 | ||
| Absent or mild | 70 (97.2) | 66 (91.7) | |
| Moderate or severe | 2 (2.8) | 6 (8.3) | |
| PLT (10E9/L) | 0.614 | ||
| ≤100 | 8 (11.1) | 10 (13.9) | |
| >100 | 64 (88.9) | 62 (86.1) | |
| ALT (U/L) | 0.590 | ||
| ≤50 | 51 (70.8) | 48 (66.7) | |
| >50 | 21 (29.2) | 24 (33.3) | |
| AST (U/L) | 0.230 | ||
| ≤40 | 31 (43.1) | 24 (33.3) | |
| >40 | 41 (56.9) | 48 (66.7) | |
| ALB (g/L) | 0.053 | ||
| ≤40 | 19 (26.4) | 30 (41.7) | |
| >40 | 53 (73.6) | 42 (58.3) | |
| TBIL (μmol/L) | 0.533 | ||
| ≤20.5 | 59 (81.9) | 56 (77.8) | |
| >20.5 | 13 (18.1) | 16 (22.2) | |
| PT (s) | 0.532 | ||
| ≤13.5 | 68 (94.4) | 65 (90.3) | |
| >13.5 | 4 (5.6) | 7 (9.7) | |
| AFP (ng/ml) | 0.230 | ||
| ≤400 | 24 (33.3) | 31 (43.1) | |
| >400 | 48 (66.7) | 41 (56.9) | |
| Child-pugh score | 0.386 | ||
| 5 | 61 (84.7) | 57 (79.2) | |
| >5 | 11 (15.3) | 15 (20.8) | |
| Number of tumor (s) | 0.736 | ||
| Single | 30 (41.7) | 32 (44.4) | |
| Multiple | 42 (58.3) | 40 (55.6) | |
| Tumor distribution | 0.278 | ||
| Uni-lobar | 53 (73.6) | 47 (65.3) | |
| Bi-lobar | 19 (26.4) | 25 (34.7) | |
| Size of largest nodule (cm) | 0.974 | ||
| <5 | 17 (23.6) | 16 (22.2) | |
| 5-10 | 34 (47.2) | 34 (47.2) | |
| >10 | 21 (29.2) | 22 (30.6) | |
| Tumor thrombus | 0.143 | ||
| Vp1 | 2 (2.8) | 1 (1.4) | |
| Vp2 | 10 (13.9) | 9 (12.5) | |
| VP3 | 51 (70.8) | 42 (58.3) | |
| VP4 | 9 (12.5) | 20 (27.8) | |
| Pre-treatment | |||
| None | 50 (69.4) | 20 (27.8) | |
| Surgery | 0 (0) | 12 (16.7) | |
| TACE | 13 (18.1) | 42 (58.3) | |
| RFA/PMCT | 2 (2.8) | 12 (16.7) | |
| HAIC | 9 (12.5) | 11 (15.3) | |
| Follow-up treatment | |||
| Surgery | 2 (2.8) | 3 (4.2) | |
| TACE | 27 (37.5) | 26 (36.1) | |
| RFA/PMCT | 6 (8.3) | 9 (12.5) | |
| TAI | 7 (9.7) | 13 (18.1) | |
| Sorafenib | 4 (5.6) | – | |
*
No. (%).
PSM, propensity score matching; HBsAg, hepatitis B surface antigen; PLT, blood platelet; ALT, alanine aminotransferase; AST, aspartate aminotransferase; ALB, albumin; TBIL, total bilirubin; PT, prothrombin time; AFP, alpha fetoprotein; TACE, transcatheter arterial chemoembolization; RFA, radiofrequency ablation; PMCT, percutaneous microwave coagulation therapy; HAIC, hepatic artery infusion chemotherapy.